BishopM. C., FellowsG.J.: Urine hydroxyproline excretion: a marker of bone in prostatic carcinoma. Brit. J. Urol., 49; 711 (1977).
2.
CushieriA., FelgateR. A.: Urinary hydroxyproline excretion in carcinoma of the breast. Brit. J. Exp. Pathol., 53; 237 (1972).
3.
GielenF., DesquekerJ., DrochmansAl, WildiersJ., MerlevedeM.: Relevance of hydroxyproline excretion to bone metastasés in breast cancer. Brit. J. Cancer, 34; 279 (1976).
4.
GuzzoC. E., PackhasW. N., PinalsR. S., KrantM. J.: Urinary hydroxyproline excretion in patients with cancer. Cancer, 24; 382 (1969).
KatzF. H., KappasA.: Influence of estradiol and estriol on urinary excretion of hydroxyproline in man. J. Lab. Clin. Med., 71; 65 (1968).
7.
KontturiM. J., SotaniemiE. A., LarmiT. K.: Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer. Scand. J. Urol. & Nephrol., 8; 91 (1974).
8.
MoopanM. M., WaxS. H., HongK., WangJ. C., TobinM. S.: Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. J. Urol., 123; 694 (1980).
9.
PowlesT. J., LeeseC. L., BondyP. K.: Hydroxyproline excretion in patients with breast cancer and response to treatment. Brit. Med. J., 2; 164 (1975).
10.
PowlesT. J., RossetG., LeeseC. L., BondyP. K.: Early morning hydroxyproline excretion in patients with breast cancer. Cancer, 38; 2564 (1976).
11.
ProckopD. J., SjoerdsmaA.: Significance of urinary hydroxyproline in man. J. Clin. Invest., 40; 843 (1967).
12.
WhitmoreW. F.: Symposium on hormones and cancer therapy; hormone therapy in prostatic cancer. Amer. J. Med., 21; 697 (1956).
